| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Magdalena Świądro-Piętoń, Dominika Dudek, Renata Wietecha-Posłuszn. Direct Immersion-Solid Phase Microextraction for Therapeutic Drug Monitoring of Patients with Mood Disorders. Molecules (Basel, Switzerland). vol 29. issue 3. 2024-02-10. PMID:38338419. |
it has been adapted to identify the most commonly used drugs in mood disorders, including amitriptyline, citalopram, fluoxetine, paroxetine, sertraline, trazodone, duloxetine, venlafaxine, lamotrigine, quetiapine, olanzapine, and mirtazapine. |
2024-02-10 |
2024-02-12 |
Not clear |
| Faruk Ugu. The Relationship Between Maternal Antidepressants and Neonatal Hypoglycemia: A Systematic Review. Alpha psychiatry. vol 22. issue 5. 2022-11-30. PMID:36447450. |
the searched keywords were as follows: antidepressants, pregnancy, selective serotonin reuptake inhibitors (ssris), citalopram, fluoxetine, paroxetine, escitalopram, sertraline, fluvoxamine, selective serotonin-norepinephrine reuptake inhibitors (snris), venlafaxine, tricyclic antidepressants (tcas), neonatal outcomes, neonatal hypoglycemia, imipramine, clomipramine, amitriptyline, bupropion, trazodone, and mirtazapine. |
2022-11-30 |
2023-08-14 |
Not clear |
| Elisabetta Gerace, Lorenzo Polenzani, Maurizio Magnani, Elisa Zianni, Gabriella Stocca, Fabrizio Gardoni, Domenico E Pellegrini-Giampietro, Renato Corradett. Antidepressant-induced increase in GluA2 expression does not translate in changes of AMPA receptor-mediated synaptic transmission at CA3/CA1 synapses in rats. Neuropharmacology. 2022-11-05. PMID:36334766. |
here, we studied whether chronic treatment with the multimodal antidepressant drug trazodone mimicked the effect of paroxetine on the expression of ampar subunits in male wistar rat hippocampus and whether these drugs produced a parallel facilitation of field excitatory postsynaptic potentials (fepsp) responses evoked by activation of ca3/ca1 synapses in dorsal hippocampal slices. |
2022-11-05 |
2023-08-14 |
rat |
| Rui Lopes, José Carlos Alves, Raquel Garcia Reg. Trazodone Addition to Paroxetine and Mirtazapine in a Patient with Treatment-Resistant Depression: The Pros and Cons of Combining Three Antidepressants. Case reports in medicine. vol 2016. 2020-10-01. PMID:27807450. |
trazodone addition to paroxetine and mirtazapine in a patient with treatment-resistant depression: the pros and cons of combining three antidepressants. |
2020-10-01 |
2023-08-13 |
Not clear |
| Rui Lopes, José Carlos Alves, Raquel Garcia Reg. Trazodone Addition to Paroxetine and Mirtazapine in a Patient with Treatment-Resistant Depression: The Pros and Cons of Combining Three Antidepressants. Case reports in medicine. vol 2016. 2020-10-01. PMID:27807450. |
we report a relapse of moderate-to-severe depressive symptoms with insomnia that successfully remitted after the addition of trazodone to a dual combination of paroxetine and mirtazapine (in standard effective doses) in a patient with treatment-resistant depression. |
2020-10-01 |
2023-08-13 |
Not clear |
| Junichi Mukai, Saki Maruyama, Katsuya Otori, Rie Kubot. [Antidepressant Medication Use and Development of Hyperglycemia and Diabetes Mellitus: A Japanese Adverse Drug Event Report Database Study]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. vol 140. issue 4. 2020-09-07. PMID:32238642. |
the lower limit of 95%ci of rors for 13 antidepressants (imipramine, clomipramine, nortriptyline, amitriptyline, amoxapine, maprotiline, mianserin, sertraline, paroxetine, escitalopram, duloxetine, mirtazapine, and trazodone), which included all subclasses, exceeded 1. |
2020-09-07 |
2023-08-13 |
Not clear |
| Maria Nardell, Rajesh R Tamp. Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials. American journal of Alzheimer's disease and other dementias. vol 29. issue 2. 2014-12-22. PMID:24164931. |
of these, 2 trials used the selective serotonin reuptake inhibitor (ssri), paroxetine; 1 trial used trazodone; 2 trials used stimulants (methylphenidate and dextroamphetamine); 1 trial used the acetylcholinesterase inhibitor, galantamine; 2 trials used the n-methyl-d-aspartate antagonist, memantine; and 1 trial used the neuropeptide oxytocin. |
2014-12-22 |
2023-08-12 |
Not clear |
| Yiru Fang, Chengmei Yuan, Yifeng Xu, Jun Chen, Zhiguo Wu, Lan Cao, Zhenghui Yi, Wu Hong, Yong Wang, Kaida Jiang, Xingjia Cui, Joseph R Calabrese, Keming Ga. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. Journal of clinical psychopharmacology. vol 31. issue 5. 2011-12-27. PMID:21869688. |
a pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult chinese patients with treatment-resistant major depression. |
2011-12-27 |
2023-08-12 |
Not clear |
| Yiru Fang, Chengmei Yuan, Yifeng Xu, Jun Chen, Zhiguo Wu, Lan Cao, Zhenghui Yi, Wu Hong, Yong Wang, Kaida Jiang, Xingjia Cui, Joseph R Calabrese, Keming Ga. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. Journal of clinical psychopharmacology. vol 31. issue 5. 2011-12-27. PMID:21869688. |
to compare the efficacy and safety of augmenting paroxetine with risperidone, buspirone, valproate, trazodone, or thyroid hormone in patients with treatment-resistant depression (trd), 225 patients with retrospectively and/or prospectively identified stage ii trd were randomly assigned to receive an 8-week treatment of paroxetine 20 mg/d augmented with risperidone 2 mg/d (n = 45), sodium valproate 600 mg/d (n = 39), buspirone 30 mg/d (n = 46), trazodone 100 mg/d (n = 47), or thyroid hormone 80 mg/d (n = 48). |
2011-12-27 |
2023-08-12 |
Not clear |
| Mark J Millan, Anne Dekeyn. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with alpha/beta-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors. The international journal of neuropsychopharmacology. vol 10. issue 5. 2008-01-17. PMID:17076935. |
in contrast, the 5-ht reuptake inhibitors, citalopram, sertraline and paroxetine (all >2.5), and the 5-ht reuptake inhibitors/5-ht2 receptor antagonists, nefazodone and trazodone (both >10.0), did not substitute for reboxetine. |
2008-01-17 |
2023-08-12 |
rat |
| Tiffany W Cho. Treatment approaches to symptoms associated with frontotemporal degeneration. Current psychiatry reports. vol 7. issue 5. 2006-01-10. PMID:16216158. |
although there is evidence to support a serotonergic deficit, and clinicians frequently prescribe selective serotonin reuptake inhibitors to patients with ftd, only paroxetine and trazodone have been studied. |
2006-01-10 |
2023-08-12 |
Not clear |
| S Kasper, L Olivieri, G Di Loreto, P Dionisi. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Current medical research and opinion. vol 21. issue 8. 2005-12-28. PMID:16083521. |
to evaluate the efficacy and safety of trazodone prolonged release compared with paroxetine in the treatment of patients with major depression. |
2005-12-28 |
2023-08-12 |
Not clear |
| S Kasper, L Olivieri, G Di Loreto, P Dionisi. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Current medical research and opinion. vol 21. issue 8. 2005-12-28. PMID:16083521. |
a comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. |
2005-12-28 |
2023-08-12 |
Not clear |
| Rajamannar Ramasubb. SSRI treatment-associated stroke: causality assessment in two cases. The Annals of pharmacotherapy. vol 38. issue 7-8. 2004-10-06. PMID:15150381. |
the second patient was a 46-year-old white woman with a history of recurrent depression who developed delirium and ischemic stroke while she was taking a combination of paroxetine 50 mg/day, trazodone 200 mg/day, and bupropion 150 mg/day. |
2004-10-06 |
2023-08-12 |
Not clear |
| J Ishigooka, T Kasahara, E Nagata, M Murasaki, S Miur. Effects of washing procedure on platelets pretreated with serotonin uptake inhibitors in vitro: low Ki values predict long-lasting inhibition of serotonin uptake in vivo. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 18. issue 1. 1998-07-22. PMID:9592808. |
among the drugs tested, those with low ki values, such as clomipramine, duloxetine and paroxetine, inhibited 5-ht uptake even after removal from the medium, while those with high ki values such as amitriptyline, desipramine, imipramine, mianserin, trazodone, and zimelidine were easily removed by washing. |
1998-07-22 |
2023-08-12 |
human |
| K R Bonson, J W Buckholtz, D L Murph. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 14. issue 6. 1996-11-27. PMID:8726753. |
twenty-eight out of 32 subjects (88%) who had taken an antidepressant with inhibitory effects on serotonin (5-ht) reuptake (fluoxetine, paroxetine, sertraline, trazodone) for over 3 weeks had a subjective decrease or virtual elimination of their responses to lsd. |
1996-11-27 |
2023-08-12 |
human |
| R R Reeves, J A Bulle. Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics. vol 36. issue 2. 1995-05-25. PMID:7724720. |
serotonin syndrome produced by paroxetine and low-dose trazodone. |
1995-05-25 |
2023-08-12 |
Not clear |
| C B Nemerof. Evolutionary trends in the pharmacotherapeutic management of depression. The Journal of clinical psychiatry. vol 55 Suppl. 1995-02-06. PMID:7814356. |
in addition to monoamine oxidase inhibitors and tricyclic and tetracyclic antidepressants, the serotonin reuptake inhibitors fluoxetine, sertraline, and paroxetine are now available, as well as a group of antidepressants with atypical mechanisms of action that includes bupropion, trazodone, venlafaxin, and nefazodone. |
1995-02-06 |
2023-08-12 |
Not clear |
| S H Preskor. Recent pharmacologic advances in antidepressant therapy for the elderly. The American journal of medicine. vol 94. issue 5A. 1993-06-30. PMID:8503477. |
the practicing clinician now has five distinct classes of antidepressant medications that may be used for treating depression in the elderly: tricyclic antidepressants (tcas; e.g., desipramine, nortriptyline), monoamine oxidase inhibitors (maois; e.g., isocarboxazid, tranylcypromine), selective serotonin reuptake inhibitors (ssris; i.e., fluoxetine, sertraline, and paroxetine), aminoketones (i.e., bupropion), and triazolopyridines (i.e., trazodone). |
1993-06-30 |
2023-08-12 |
Not clear |
| P Bauman. Clinical pharmacokinetics of citalopram and other selective serotonergic reuptake inhibitors (SSRI). International clinical psychopharmacology. vol 6 Suppl 5. 1992-12-23. PMID:1431018. |
within the last years, several new and more selective serotonin uptake inhibitors have been introduced in clinical practice, including trazodone, citalopram, paroxetine, femoxetine, fluvoxamine and fluoxetine. |
1992-12-23 |
2023-08-11 |
Not clear |